SCHEMBL2283536

SCHEMBL2283536

C=CCOc1cc(OC)c(C(=O)/C=C/c2ccc(Br)cc2)c(OCC=C)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.72
MDM2 Q00987 1/20 0.72
FLT3 P36888 1/20 0.60
ABCG2 Q9UNQ0 4/20 0.60
SLC5A1 P13866 1/20 0.54
SLC5A2 P31639 1/20 0.54
TDP1 Q9NUW8 3/20 0.52
NFKB1 P19838 1/20 0.50
DPP4 P27487 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
CXCL12 P48061 1/20 0.49
CYP3A4 P08684 3/20 0.48
MAPT P10636 3/20 0.48
KMT2A Q03164 3/20 0.48
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 2/20 0.48
HPGD P15428 2/20 0.48
MCL1 Q07820 1/20 0.48
MAOA P21397 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2283541 1.00 TP53 (0.72) TP53MDM2FLT3ABCG2SLC5A1
SCHEMBL2284259 0.91 FLT3 (0.73) TP53MDM2FLT3ABCG2SLC5A1
SCHEMBL2284249 0.91 FLT3 (0.73) TP53MDM2FLT3ABCG2SLC5A1
SCHEMBL2283498 0.90 FLT3 (0.61) TP53MDM2FLT3ABCG2SLC5A1
SCHEMBL30383403 0.90 NFKB1 (0.63) TP53MDM2FLT3ABCG2SLC5A1
SCHEMBL2286892 0.90 NFKB1 (0.63) TP53MDM2FLT3ABCG2SLC5A1
SCHEMBL2283509 0.90 FLT3 (0.61) TP53MDM2FLT3ABCG2SLC5A1
SCHEMBL2286904 0.90 NFKB1 (0.63) TP53MDM2FLT3ABCG2SLC5A1
SCHEMBL2282340 0.89 FLT3 (0.60) TP53MDM2FLT3ABCG2SLC5A1
SCHEMBL2283524 0.89 FLT3 (0.60) TP53MDM2FLT3ABCG2SLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9061984-B2 Compounds related to chalcones and benzothienopyrimidines, their synthesis, and uses to treat diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2015-06-23 US disclosed
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES THE JOHNS HOPKINS UNIVERSITY 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES TERT, TYMS, NISCH TP53 396/4885MDM2 1890/4885FLT3 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.